Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Resverlogix Corp

RVX.TO ✗ NOT COMPLIANT ☆ Track — members

TSX · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.08

▲ +0.00%

Market Cap $25.92M · Vol 7.54K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$25.92M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

50.00

Momentum

Beta

1.09

vs Market

52W High

$0.11

29.61% below

52W Low

$0.06

22.97% above

Volume

7.54K

Avg 30.93K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

73.11%

Public shares

Shariah Compliance8 STANDARDS

✗ Resverlogix Corp (RVX.TO) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RVX.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.53%

+5.00%

+10.53%

YTD

+5.00%

-4.55%

+2.16%

-83.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,767,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-101.44% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	343.92M

Technical Indicators

50-Day SMA	$0.07
200-Day SMA	$0.07
RSI (14)	50.00
Beta	1.09
52-Week High	$0.11
52-Week Low	$0.06

Volume Today	7.54K
Avg Daily Volume (30D)	30.93K
Relative Volume	0.24x
Volatility (10D)	82.82
Volatility (30D)	72.19
Free Float	73.11%

Analyst Consensus

N/A

Current Price $0.08

Mean Target N/A

52W Low$0.06 52W High$0.11

Current

Target

$0.06 $0.11

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX

FIGIBBG001SJQHY2

ISINCA76128M1086

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.